NurExone Biologic (J90) Stock Statistics & Valuation Metrics
Total Valuation
NurExone Biologic has a market cap or net worth of EUR 23.74M. The enterprise value is EUR 49.36M.
- Market Cap
- EUR 23.74M
- Enterprise Value
- EUR 49.36M
Share Statistics
NurExone Biologic has 77,746,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 77,746,750
- Owned by Insiders
- 0.22%
- Owned by Institutions
- ―
Financial Efficiency
NurExone Biologic’s return on equity (ROE) is -2.31 and return on invested capital (ROIC) is -201.88%.
- Return on Equity (ROE)
- -2.31
- Return on Assets (ROA)
- -1.56
- Return on Invested Capital (ROIC)
- -201.88%
- Return on Capital Employed (ROCE)
- -2.04
- Revenue Per Employee
- 0
- Profits Per Employee
- -375.53K
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NurExone Biologic is -4.45. NurExone Biologic’s PEG ratio is -0.26.
- PE Ratio
- -4.45
- PS Ratio
- 0.00
- PB Ratio
- 24.70
- Price to FCF
- -5.60
- Price to Operating Cash Flow
- -6.73
- PEG Ratio
- -0.26
Income Statement
In the last 12 months, NurExone Biologic had revenue of 0 and earned -6.38M in profits. Earnings per share was -0.08.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -6.32M
- Pretax Income
- -6.38M
- Net Income
- -6.38M
- EBITDA
- -6.17M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -4.65M and capital expenditures -57,000, giving a free cash flow of -4.71M billion.
- Operating Cash Flow
- -4.65M
- Free Cash Flow
- -4.71M
- Free Cash Flow per Share
- -0.05
Dividends & Yields
NurExone Biologic pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -17.86%
- Earnings Yield
- -20.17%
Stock Price Statistics
- Beta
- -0.17
- 52-Week Price Change
- -28.10%
- 50-Day Moving Average
- 0.35
- 200-Day Moving Average
- 0.35
- Relative Strength Index (RSI)
- 50.61
- Average Volume (3m)
- 8,634
Important Dates
NurExone Biologic upcoming earnings date is Nov 20, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Nov 20, 2026
- Ex-Dividend Date
- ―
Financial Position
NurExone Biologic as a current ratio of 2.63, with Debt / Equity ratio of 3.92%
- Current Ratio
- 2.63
- Quick Ratio
- 2.63
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.33
- Interest Coverage Ratio
- -203.97
Taxes
In the past 12 months, NurExone Biologic has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NurExone Biologic EV to EBITDA ratio is -4.18, with an EV/FCF ratio of -5.40.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.18
- EV to Free Cash Flow
- -5.40
- EV to Operating Cash Flow
- -5.46
Balance Sheet
NurExone Biologic has EUR 1.01M in cash and marketable securities with EUR 52.00K in debt, giving a net cash position of EUR 954.00K billion.
- Cash & Marketable Securities
- EUR 1.01M
- Total Debt
- EUR 52.00K
- Net Cash
- EUR 954.00K
- Net Cash Per Share
- EUR 0.01
- Tangible Book Value Per Share
- EUR 0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for NurExone Biologic is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 23.80%
